Elekta reports Gamma Knife data as Elekta stock trades at EUR 4.59 versus the EUR 4.59 close

Published on 10/04/2026 at 18:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock trades at EUR 4.59 in weekend trading on October 4, 2026 versus its EUR 4.59 close. Gamma Knife data covered up to 50 brain metastases.

Extreme Makroaufnahme präziser metallischer Zahnräder und Bauteile in kühlem Blaulicht — Makroaufnahme präziser Metallkomponenten illustriert die technische Fertigungsqualität hinter Produkten von Elekta AB SE0000163628 im Detail, Illustration mit AI erstellt.

On September 29, 2026, Elekta announced new phase 2 data on Leksell Gamma Knife radiosurgery in patients with up to 50 brain metastases, according to an Elekta release. At 6:34 p.m. CEST on October 4, 2026, Lang & Schwarz showed Elekta stock at EUR 4.59 in weekend trading, unchanged at 0.00 percent versus the EUR 4.59 close at Lang & Schwarz on October 2, 2026.

Weekend trading

The Lang & Schwarz bid was EUR 4.58 and the ask was EUR 4.60 at 6:34 p.m. CEST on October 4, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Elekta stock.

Gamma Knife study

The study, conducted by researchers at Sunnybrook Health Sciences Centre in Toronto, evaluated focal stereotactic radiosurgery in patients with 5 to 50 brain metastases. Results showed favorable memory performance two months after treatment, while investigators reported no difference in time to meaningful cognitive decline between patients with 21 to 50 metastases and those with 5 to 20 metastases, the company said.

In a separate September 27, 2026 announcement, Elekta said it had expanded its adaptive radiotherapy portfolio across CT-guided, MR-guided, radiosurgery and brachytherapy workflows. The company identified new online adaptive capability for Elekta Harmony and real-time adaptive planning for Elekta Prostate Guideway in its portfolio release.